Akihiro Takamiya

Dr. Akihiro Takamiya


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 October 2018 in Molecular Psychiatry
Verified
Journal Article
Open access
PDF file
SMSho Moriguchi
Sho Moriguchi
ATAkihiro Takamiya
Akihiro Takamiya
Yoshihiro NodaYoshihiro Noda
Yoshihiro Noda
NHNobuyuki Horita
Nobuyuki Horita
MWMasataka Wada
Masataka Wada
SNShinichiro Nakajima
Shinichiro Nakajima
Alterations in glutamatergic neurotransmission are implicated in the pathophysiology of depression, and the glutamatergic system represents a treatment target for depression. To summarize the nature of glutamatergic alterations in patients with depression, we conducted a meta-analysis of proton magnetic resonance (1H-MRS) spectroscopy studies examining levels of glutamate. We used the search terms: depress* AND (MRS OR “magnetic resonance spectroscopy”). The search was performed with MEDLINE, Embase, and PsycINFO. The inclusion criteria were 1H-MRS studies comparing levels of glutamate + glutamine (Glx), glutamate, or glutamine between patients with depression and healthy controls. Standardized mean differences (SMD) were calculated to assess group differences in the levels of glutamatergic neurometabolites. Forty-nine studies met the eligibility criteria, which included 1180 patients and 1066 healthy controls. There were significant decreases in Glx within the medial frontal cortex (SMD = −0.38; 95% CI, −0.69 to −0.07) in patients with depression compared with controls. Subanalyses revealed that there was a significant decrease in Glx in the medial frontal cortex in medicated patients with depression (SMD = −0.50; 95% CI, −0.80 to −0.20), but not in unmedicated patients (SMD = −0.27; 95% CI, −0.76 to 0.21) compared with controls. Overall, decreased levels of glutamatergic metabolites in the medial frontal cortex are linked with the pathophysiology of depression. These findings are in line with the hypothesis that depression may be associated with abnormal glutamatergic neurotransmission.

1 February 2019 in Frontiers in Human Neuroscience
Verified
Journal Article
Open access
PDF file
ATAkihiro Takamiya
Akihiro Takamiya
JHJinichi Hirano
Jinichi Hirano
BYBun Yamagata
Bun Yamagata
STShigeki Takei
Shigeki Takei
TKTaishiro Kishimoto
Taishiro Kishimoto
MMMasaru Mimura
Masaru Mimura
Introduction: Electroconvulsive therapy (ECT) has antidepressant effects, but it also has possible cognitive side effects. The effects of ECT on neuronal oscillatory pattern and phase synchronization, and the relationship between clinical response or cognitive change and electroencephalogram (EEG) measurements remain elusive. Methods: Individuals with unipolar depressive disorder receiving bilateral ECT were recruited. Five minutes of resting, eyes-closed, 19-lead EEG recordings were obtained before and after a course of ECT. Non-overlapping 60 artifact-free epocs of 2-s duration were used for the analyses. We used exact low resolution electromagnetic tomography (eLORETA) to compute the whole-brain three-dimensional intracortical distribution of current source density (CSD) and phase synchronization among 28 regions-of-interest (ROIs). Paired t-tests were used to identify cortical voxels and connectivities showing changes after ECT. Montgomery Asberg Depression Rating Scale (MADRS) and Mini-Mental State Examination (MMSE) were used to evaluate the severity of depression and the global cognitive function. Correlation analyses were conducted to identify the relationship between changes in the EEG measurements and changes in MADRS or MMSE. Results: Thirteen depressed patients (five females, mean age: 58.4 years old) were included. ECT increased theta CSD in the anterior cingulate cortex (ACC), and decreased beta CSD in the frontal pole (FP), and gamma CSD in the inferior parietal lobule (IPL). ECT increased theta phase synchronization between the posterior cingulate cortex (PCC) and the anterior frontal cortex, and decreased beta phase synchronization between the PCC and temporal regions. A decline in beta synchronization in the left hemisphere was associated with cognitive changes after ECT. Conclusion: ECT modulated resting-state EEG oscillatory patterns and phase synchronization in central nodes of the default mode network (DMN). Changes in beta synchronization in the left hemisphere might explain the ECT-related cognitive side effects.

1 June 2019 in Journal of Affective Disorders
Verified
Journal Article
Closed access
YTYuuki Tazawa
Yuuki Tazawa
MWMasataka Wada
Masataka Wada
YMYasue Mitsukura
Yasue Mitsukura
ATAkihiro Takamiya
Akihiro Takamiya
MKMomoko Kitazawa
Momoko Kitazawa
TKTaishiro Kishimoto
Taishiro Kishimoto

4 January 2018 in The British Journal of Psychiatry
Verified
Journal Article
Open access
PDF file
ATAkihiro Takamiya
Akihiro Takamiya
JCJun Ku Chung
Jun Ku Chung
KLKuo-Ching Liang
Kuo-Ching Liang
AGAriel Graff-Guerrero
Ariel Graff-Guerrero
MMMasaru Mimura
Masaru Mimura
TKTaishiro Kishimoto
Taishiro Kishimoto
Background: Electroconvulsive therapy (ECT) is one of the most effective treatments for depression, although the underlying mechanisms remain unclear. Animal studies have shown that electroconvulsive shock induced neuroplastic changes in the hippocampus.Aims: To summarise volumetric magnetic resonance imaging studies investigating the effects of ECT on limbic brain structures.Method: A systematic review and meta-analysis was conducted to assess volumetric changes of each side of the hippocampus and amygdala before and after ECT. Standardised mean difference (SMD) was calculated.Results: A total of 8 studies (n = 193) were selected for our analyses. Both right and left hippocampal and amygdala volumes increased after ECT. Meta-regression analyses revealed that age, percentage of those responding and percentage of those in remission were negatively associated with volume increases in the left hippocampus.Conclusions: ECT increased brain volume in the limbic structures. The clinical relevance of volume increase needs further investigation.Declaration of interest: None.

1 March 2020 in Biological Psychiatry
Verified
Journal Article
Open access
OOOlga Therese Ousdal
Olga Therese Ousdal
MAMiklos Argyelan
Miklos Argyelan
KNKatherine L. Narr
Katherine L. Narr
CAChristopher C. Abbott
Christopher C. Abbott
BWBenjamin Wade
Benjamin Wade
PSPascal Sienaert
Pascal Sienaert
Electroconvulsive therapy (ECT) is associated with volumetric enlargements of corticolimbic brain regions. However, the pattern of whole-brain structural alterations following ECT remains unresolved. Here, we examined the longitudinal effects of ECT on global and local variations in gray matter, white matter, and ventricle volumes in patients with major depressive disorder as well as predictors of ECT-related clinical response. Longitudinal magnetic resonance imaging and clinical data from the Global ECT-MRI Research Collaboration (GEMRIC) were used to investigate changes in white matter, gray matter, and ventricle volumes before and after ECT in 328 patients experiencing a major depressive episode. In addition, 95 nondepressed control subjects were scanned twice. We performed a mega-analysis of single subject data from 14 independent GEMRIC sites. Volumetric increases occurred in 79 of 84 gray matter regions of interest. In total, the cortical volume increased by mean ± SD of 1.04 ± 1.03% (Cohen's d = 1.01, p < .001) and the subcortical gray matter volume increased by 1.47 ± 1.05% (d = 1.40, p < .001) in patients. The subcortical gray matter increase was negatively associated with total ventricle volume (Spearman's rank correlation ρ = -.44, p < .001), while total white matter volume remained unchanged (d = -0.05, p = .41). The changes were modulated by number of ECTs and mode of electrode placements. However, the gray matter volumetric enlargements were not associated with clinical outcome. The findings suggest that ECT induces gray matter volumetric increases that are broadly distributed. However, gross volumetric increases of specific anatomically defined regions may not serve as feasible biomarkers of clinical response.

1 February 2020 in Heliyon
Verified
Journal Article
Open access
YTYuuki Tazawa
Yuuki Tazawa
KLKuo-Ching Liang
Kuo-Ching Liang
MYMichitaka Yoshimura
Michitaka Yoshimura
MKMomoko Kitazawa
Momoko Kitazawa
YKYuriko Kaise
Yuriko Kaise
TKTaishiro Kishimoto
Taishiro Kishimoto
We aimed to develop a machine learning algorithm to screen for depression and assess severity based on data from wearable devices. We used a wearable device that calculates steps, energy expenditure, body movement, sleep time, heart rate, skin temperature, and ultraviolet light exposure. Depressed patients and healthy volunteers wore the device continuously for the study period. The modalities were compared hourly between patients and healthy volunteers. XGBoost was used to build machine learning models and 10-fold cross-validation was applied for the validation. Forty-five depressed patients and 41 healthy controls participated, creating a combined 5,250 days' worth of data. Heart rate, steps, and sleep were significantly different between patients and healthy volunteers in some comparisons. Similar differences were also observed longitudinally when patients' symptoms improved. Based on seven days' data, the model identified symptomatic patients with 0.76 accuracy and predicted Hamilton Depression Rating Scale-17 scores with a 0.61 correlation coefficient. Skin temperature, sleep time-related features, and the correlation of those modalities were the most significant features in machine learning. The small number of subjects who participated in this study may have weakened the statistical significance of the study. There are differences in the demographic data among groups although we performed a correction for multiple comparisons. Validation in independent datasets was not performed, although 10-fold cross validation with the internal data was conducted. The results indicated that utilizing wearable devices and machine learning may be useful in identifying depression as well as assessing severity.